1896 results about "Drugs preparations" patented technology

The invention provides a preparation method of medicinal liquor and application of the medicinal liquor in preparation of antioxidant and anti-aging products, and relates to the technical field of medicinal preparations. The preparation method comprises the following steps: (1) crushing; (2) extracting; (3) standing and separating; and (4) freezing and filtering to obtain the medicinal liquor. The medicinal liquor is obtained by extracting the traditional Chinese medicine components through the steps of crushing in batches, mixing and extracting, standing, freezing and separating the supernate and the suspension in different separation modes, and the medicinal liquor can better improve the space exploration capability of a mouse aged due to D-galactose, can reduce malondialdehyde MDA, and can improve the immunity of the mouse. The activity of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) is improved, and the obvious anti-oxidation and anti-aging effects are achieved.

The invention relates to the technical field of pharmaceutical preparations, and discloses a composition with liver protection and antioxidation effects and a preparation method thereof.The composition is prepared from galactosamine modified astragalus membranaceus exosome, schisandra chinensis nanocrystals, liquorice-chitosan nanoparticles, lactobacillus acidophilus freeze-dried powder, beta-(1, 3) / (1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate) sourced from saccharomyces cerevisiae, and beta-(1, 3, 4-tetramethyl-1, 3-pentanediol monoisobutyrate). And (6) a dextran, grape exosome-curcumin hybrid vesicle freeze-dried powder, a curcumin-mitochondrial targeting peptide compound, a resveratrol-hydroxypropyl-beta-cyclodextrin inclusion compound and reduced panthenol. According to the liver-protecting and anti-oxidation composition disclosed by the invention, multi-dimensional intervention on liver protection is realized through an elaborately designed ternary system. The system is composed of a traditional Chinese medicine extract, a microorganism-plant exosome combination and a high-bioavailability antioxidant, all the parts have a synergistic effect, and the liver protection effect is remarkably improved.

The invention provides a combined fermented product of ginseng, astragalus membranaceus and donkey-hide gelatin as well as a preparation method and application of the combined fermented product, and relates to the technical field of pharmaceutical preparations. The combined leavening is obtained by fermenting ginseng, astragalus membranaceus and donkey-hide gelatin, and the mass ratio of the ginseng to the astragalus membranaceus to the donkey-hide gelatin is (1-3): (10-30): 1. The composition of ginseng, astragalus membranaceus and colla corii asini is subjected to probiotic fermentation, macromolecular saponin is converted into aglycone or secondary saponin with smaller molecules, protein is split into peptide chains with smaller molecules, polysaccharide is split into sugar chains with smaller molecules, absorption and utilization of effective components of the medicine are facilitated, and the effect of tonifying qi and blood can be rapidly achieved.

The invention relates to a mulberry leaf flavone microcapsule as well as a preparation method and application thereof, and belongs to the technical field of microcapsule drug loading. The preparation method of the mulberry leaf flavone microcapsule comprises the following steps: S1, adding mulberry leaf flavone into a chitosan solution, carrying out ultrasonic treatment, shearing by using a homogenizer, and heating and stirring to obtain a mixed solution; s2, slowly dropwise adding a sodium tripolyphosphate solution into the mixed solution, reacting and curing until the solution becomes milk white liquid from clear and no precipitate is generated, then centrifuging and washing, and collecting particles; and S3, freezing the particles, and performing freeze drying to obtain the mulberry leaf flavone microcapsules. The mulberry leaf flavone microcapsule provided by the invention can be used for developing a novel medicinal preparation in the field of medicines, and can relieve disease symptoms and delay disease progression through the antioxidant and anti-inflammatory characteristics of the mulberry leaf flavone microcapsule; in the field of food, the method can be applied to development of functional food, for example, the method can be added into beverages and health-care products to provide health benefits of antioxidation, blood fat reduction and the like for consumers.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention discloses a nano-drug preparation system and a nano-drug preparation process. The nano-drug preparation system comprises a micro-fluidic chip, at least two feeding devices and a controller, the two feeding devices are communicated with the micro-fluidic chip and are respectively used for conveying different raw material liquids; each feeding device comprises a liquid path reversing coordination integrated block and two sucking and pushing mechanisms; the liquid path reversing coordination integrated block is provided with an input end and an output end; the two sucking and pushing mechanisms are both communicated with a fluid channel of the liquid path reversing coordination integrated block, each sucking and pushing mechanism achieves input or output of raw material liquid in a sucking or pushing mode, the driving ends of the two sucking and pushing mechanisms are both in signal connection with the controller, and the controller is used for controlling the two sucking and pushing mechanisms to alternately operate in the reverse direction; a one-way valve assembly is arranged in the liquid path reversing coordination integrated block. By means of the arrangement, the function of stably and continuously conveying raw material liquid without liquid mixing is achieved, the controllability of the preparation process of nano-drugs in the micro-fluidic chip is guaranteed, and the purpose of improving the preparation effect is achieved.

The invention belongs to the field of pharmaceutical preparations, and relates to a brexpiprazole long-acting microsphere and a preparation method thereof, and the preparation method comprises the following steps: (1) dissolving brexpiprazole and a degradable polymer in an organic solvent to obtain a drug-containing polymer solution as an oil phase; (2) mixing the drug-containing polymer solution with a polyvinyl alcohol solution through a microfluidic technology to obtain an oil-in-water emulsion; and (3) under a stirring condition, carrying out curing, washing and freeze drying on the oil-in-water type emulsion to obtain the brexpiprazole long-acting microspheres. By adjusting the volatilization stirring time when the O / W primary emulsion is formed, the final in-vitro release rate of the microspheres is adjusted, and the microspheres which are free of burst release and hysteresis period and are slowly released can be screened out. The brexpiprazole long-acting microsphere provided by the invention is simple in preparation process, easy to industrially amplify, high in encapsulation efficiency, large in drug loading capacity, uniform in microsphere particle size distribution, round in shape, good in flowability and good in needle passing property, is easier to inject, has an obvious slow release effect, and can be used for reducing the fluctuation of blood concentration and effectively improving the compliance of psychiatric patients.

The invention provides a novel crystal form of rosemeltirome and a preparation method thereof. And the crystal form of the APTI-II and the crystal form of the APTI-III are as follows. The crystal forms are easy to prepare and high in purity. Particularly, the crystal form APTI-III has good stability and good solubility in a water solvent, and is suitable for industrial large-scale production and preparation of pharmaceutical preparations.

The invention relates to the technical field of pharmacy management, in particular to a clinical pharmacy intelligent management method and system and a storage medium. The method comprises the following steps: acquiring total element data of a drug treatment chain in real time, wherein the total element data comprises a prescription instruction stream, a drug preparation parameter, a drug administration execution record and a patient physiological feedback signal; constructing a drug treatment chain dynamic evaluation engine; establishing a digital twinning mapping relationship between the administration operation and the clinical terminal for the total element data of the drug treatment chain by utilizing a drug treatment chain dynamic evaluation engine, and generating a drug digital relationship chain; and performing drug treatment chain breakage risk point identification on the drug digital relation chain based on a multi-dimensional deviation detection algorithm to obtain drug treatment abnormal risk points. Through real-time data acquisition, digital twinborn mapping and intelligent risk identification and intervention, intelligent management and accurate regulation and control of the drug treatment chain are improved, and intelligence and accuracy of drug treatment chain management are improved.

The invention provides a benzofuranone compound as well as a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The benzofuranone compound is a compound as shown in a formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The benzofuranone compound and the pharmaceutical composition and the pharmaceutical preparation prepared from the benzofuranone compound can prevent or treat organ injury diseases, and have good treatment effects in kidney injury, liver injury, lung injury, brain injury and heart injury.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a meloabalin besylate double-release preparation and a preparation method thereof. Comprising a quick-release pellet and a sustained-release pellet, and the quick-release pellet and the sustained-release pellet are wrapped in a hollow capsule; the quick-release pellet comprises a quick-release blank pellet core, a quick-release drug layer and a quick-release film coating layer; the sustained-release pellet comprises a sustained-release blank pellet core, a sustained-release drug layer, a sustained-release layer and a sustained-release film coating layer. According to the invention, the stable blood concentration is obtained while the medicine effect takes effect quickly, the medicine taking frequency is reduced, convenience is brought to patients, and the compliance is improved. The invention also provides a preparation method thereof.

The invention relates to application of a platelet reaction protein 4 in preparation of an alopecia medicine, and belongs to the field of medical biology. The invention aims to solve the technical problems of limited curative effect, obvious side effect and narrow application range of the existing alopecia treatment medicine. The invention provides an application of a platelet reaction protein 4 (THBS4) in preparation of an alopecia medicinal preparation, which can promote hair follicles to be converted from a resting period to a growing period by regulating and controlling a mechanical microenvironment around the hair follicles, enhancing the interaction between fibroblasts and hair follicle stem cells and activating regeneration signal channels in hair papilla and hair bud areas. The traditional Chinese medicine composition breaks through the limitation that existing treatment only aims at specific alopecia types, and can be widely applied to various alopecia diseases such as androgenetic alopecia, pressure alopecia and alopecia after chemotherapy. And compared with the traditional medicine, the traditional Chinese medicine composition has the advantages of quick response, no skin irritation reaction and improved hair follicle regeneration efficiency, and provides a brand new solution for safe and efficient treatment of alopecia.

The invention belongs to the technical field of pharmaceutical analysis, and relates to a method for detecting the content of povidone K30. According to the method, the content of povidone K30 in the medicinal preparation is detected by adopting a high performance liquid chromatography; detection conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18-AQ column; a mobile phase is a phosphate solution. The method has the characteristics of high accuracy, strong specificity and the like for detecting the content of povidone K30 in the pharmaceutical preparation, can overcome the interference of other auxiliary materials in the pharmaceutical preparation, and has important application value in development and consistency evaluation of the pharmaceutical preparation.

The invention relates to the technical field of pharmaceutical preparations, and provides a minoxidil film coating agent as well as a preparation method and application thereof. The minoxidil film coating agent provided by the invention comprises 40-60% of propylene glycol, 3-7% of polyvinyl alcohol, 20-30% of ethanol, 1-7% of minoxidil and the balance of water. According to the invention, propylene glycol is taken as a solvent, a plasticizer and a transdermal absorption enhancer, polyvinyl alcohol is taken as a film-forming material, and ethanol is taken as a volatile agent, after administration, ethanol is volatilized to promote film formation of polyvinyl alcohol, and propylene glycol enhances the plasticity of the formed film, so that the effect of reducing liquid medicine loss is achieved, the local medicine concentration is increased, and the bioavailability is improved. The minoxidil liniment disclosed by the invention has excellent skin permeability, can effectively convey a medicine to a required part, and can ensure that the medicine is released at a fixed position of the skin and is accurately administered in a medicine release process, so that the stimulation of liquid medicine flow to other parts is reduced, and a good treatment effect is achieved.

The invention discloses klebsiella aerogenes HW2024 and application of the klebsiella aerogenes HW2024 in preparation of drugs for treating allergic rhinitis. The preservation number of the klebsiella aerogenes HW2024 is CCTCC NO: M 20252524. The Klebsiella aerogenes disclosed by the invention is a symbiotic bacterium, and is relatively safe and easy to obtain, so that the treatment cost of AR patients can be greatly reduced, and a new treatment choice is provided for AR treatment; the pharmaceutical preparation for treating allergic rhinitis is simple and convenient in administration route, easy to operate and convenient for patients to use.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention relates to euphausia superba peptide with uric acid reducing activity and application thereof. The euphausia superba peptide is a short peptide obtained by extraction, enzymolysis, separation and purification from degreased euphausia superba powder, and the amino acid sequence of the euphausia superba peptide is Ser-Ala-Gly-Lys-Thr. Researches show that the peptide can reduce the generation of uric acid by inhibiting the activity of xanthine oxidase and promote the excretion of uric acid. In-vitro cell experiments prove that under the concentration of 10 mu M, the inhibition rate of the peptide on xanthine oxidase reaches 23.1%; animal experiments show that the blood uric acid level of mice in a high-dose group (50mg / kg) is reduced by about 40% compared with that in a model group. The invention also develops a health-care beverage and a medicinal preparation which take the peptide as an active component, and provides a new choice for preventing and treating hyperuricemia and gout.

The invention discloses a mussel byssus polypeptide with antibacterial performance and application thereof.The mussel byssus polypeptide has an obvious inhibiting effect on gram-positive bacteria and gram-negative bacteria, can inhibit formation of biological membranes of the gram-positive bacteria and the gram-negative bacteria, shows different antibacterial activities on multiple drug-resistant bacteria, and has the advantages that the mussel byssus polypeptide can be used for preparing a drug-resistant agent; and the hydrogel has low cytotoxicity and good biocompatibility, and shows good adhesion capability. The polypeptide is short in peptide chain and small in molecular weight, is a micromolecular polypeptide with great value, shows wide application potential in multiple fields, and has important value in the fields of medicine preparation, medical equipment and daily chemical products.

The invention relates to sterile bispentadol sebacate, a preparation method thereof and medical application of a medicinal preparation containing the sterile bispentadol sebacate. Wherein the particle size D50 of the sterile bis (tapentadol) sebacate is 0.5 to 10 [mu] m. The invention also provides application of the bispentadol sebacate in preparation of various acute and chronic pain medicines, and the bispentadol sebacate has the characteristic of remarkable long-acting effect.

The invention belongs to the field of pharmaceutical preparations, and particularly discloses a preparation method of a ganoderma lucidum bitter-inhibiting and taste-masking microcapsule, and the ganoderma lucidum bitter-inhibiting and taste-masking microcapsule is prepared from the following raw and auxiliary materials in parts by weight: 1 part of ganoderma lucidum water extract, 2.5-7.5 parts of chitosan solution and 2.5-7.5 parts of sodium alginate solution. According to the invention, the ganoderma lucidum water extract and the sodium alginate solution are respectively and simultaneously dripped into the chitosan solution, the ganoderma lucidum bitter-inhibiting and taste-masking microcapsule prepared by matching the specific process and corresponding process parameters has an obvious'white-in-black 'core-shell structure, the ganoderma lucidum water extract serving as a core material is successfully embedded by the gelatinized chitosan-sodium alginate serving as a wall material, and the ganoderma lucidum bitter-inhibiting and taste-masking microcapsule can be used for preparing the bitter-inhibiting and taste-masking microcapsule. The bitter taste of the lucid ganoderma can be effectively covered, the particle size and dispersion coefficient are low, the quality is stable, and the method has practical popularization and application values.

The invention relates to the technical field of pharmaceutical preparations, in particular to a docetaxel oral self-microemulsion composition and a preparation process thereof. The docetaxel oral self-microemulsion composition is prepared from docetaxel, an oil phase, a surfactant, a cosurfactant, a stabilizer and an antioxidant, the oil phase is caprylic / capric acid mono / diglyceride, medium chain triglyceride, caprylic acid propylene glycol ester or lauric acid propylene glycol ester. The docetaxel oral self-microemulsion composition provided by the invention has relatively high drug loading capacity, good physical and chemical stability and relatively high bioavailability, and is more suitable for clinical medication.

The invention discloses a preparation method of omasycine tosylate for injection, and belongs to the technical field of pharmaceutical preparations. The preparation method of the olmacycline tosylate for injection comprises the following steps: filtering a mixture solution containing the olmacycline tosylate, the cane sugar, the pH regulator and the water for injection, filling and sealing, and freeze-drying to obtain the olmacycline tosylate for injection. According to the preparation method, the problem that in the prior art, intermediate product liquid medicine is not completely dissolved is solved, the prepared freeze-dried product is free of the problems of atrophy, collapse, bottom sticking, layering and the like, the preparation method is simple, easy to operate and reliable, the obtained freeze-dried product is low in moisture content and impurity content, the stability is improved, and the product quality is guaranteed.

The invention relates to the technical field of pharmaceutical preparations, in particular to a stable perindopril amlodipine tablet and a preparation method thereof, and the tablet comprises the following components in percentage by weight: 5.0% of arginine perindopril; 3.5% of amlodipine besylate; 20%-40% of pregelatinized starch; 40%-68% of a microcrystalline cellulose colloidal silicon dioxide compound; 2.5%-6% of a disintegrating agent, wherein the disintegrating agent is selected from one or more of ion exchange resin, sodium alginate and croscarmellose sodium; the pregelatinized starch and the microcrystalline cellulose colloidal silicon dioxide compound are selected as main diluents, so that the Maillard reaction possibly occurring between the lactose and the active pharmaceutical ingredients is completely avoided, the problem of increase of related substances is fundamentally solved, and the stability and the safety of the product are remarkably improved.

The invention relates to the technical field of cell drug preparation process optimization, in particular to an umbilical cord stem cell drug preparation parameter optimization method utilizing machine learning, which comprises the following steps: preprocessing to generate a control input time sequence and an observation output time sequence, and forming a process instruction library; constructing an intervening state space model based on the two types of time sequences, and assimilating the intervening state space model; defining multiple targets and constraints, compiling a process, simulating on the model, determining a feasible region by combining statistical calibration and formalized verification, and generating a feasibility judgment function; and carrying out microparameterization on the process in the feasible region and optimizing under constraints, carrying out rolling solution according to a preset prediction window in the model prediction control framework, outputting an optimal process flow and a monitoring threshold value, and executing record backflow updating. According to the method, the replicability, the compliance and the cross-batch robustness of the process are enhanced.

The invention relates to a nano assembly for self-synergistically enhancing ferroptosis as well as a preparation method and application of the nano assembly, and belongs to the technical field of pharmaceutical preparation combined treatment of new auxiliary materials and new dosage forms. The invention firstly provides a functional conjugate linker capable of automatically generating ROS, the functional conjugate linker comprises artesunate-ferrocene or dihydroartemisinin-ferrocene, and the structural formulas of the functional conjugate linker and the artesunate-ferrocene or dihydroartemisinin-ferrocene are respectively shown as a and b. According to the present invention, the ROS self-generating functional conjugate linker and the ferroptosis inducer are co-assembled to form the nanometer assembly, such that the ROS level in the tumor cells can be effectively and synergistically improved by the ROS self-generating functional conjugate linker and the ferroptosis inducer so as to cause the tumor cell lipid peroxidation storm, and the ferroptosis induction effect can be significantly improved. The co-assembled nano preparation provided by the invention provides a new strategy and more choices for developing the delivery of drugs, and meets the urgent requirements of efficient and diversified ferroptosis-based cancer treatment strategies on preparations in clinic. # imgabs0 #

The invention belongs to the technical field of biological medicines, and particularly relates to application of a small molecule compound P7C3 in preparation of a pharmaceutical preparation for inhibiting hepatic fibrosis. According to the invention, a CCl4-induced hepatic fibrosis mouse model is used for verifying the treatment effect of P7C3 on hepatic fibrosis. Meanwhile, the influence of P7C3 on HSC activation and proliferation is verified, eIF4A1 is a direct target of P7C3 for inhibiting HSC activation, and P7C3 is a promising anti-hepatic fibrosis therapeutic drug and an effective eIF4A1 inhibitor.

The present disclosure relates to the technical field of microsphere drug preparations, in particular to an octreotide acetate sustained-release microsphere as well as a preparation method therefor and use thereof. The preparation method includes the following steps: S1, dissolving a polylactic acid-co-glycolic acid copolymer in a first organic solvent to prepare an oil phase 1; and dissolving octreotide acetate in a second organic solvent to prepare an oil phase 2; S2, adding the oil phase 2 into the oil phase 1 under stirring conditions to obtain a suspension containing octreotide acetate; S3, transferring the suspension to an aqueous phase, and performing emulsifying to obtain a semi-cured drug-loaded microsphere; and S4, transferring the semi-cured drug-loaded microsphere to a curing phase, and removing the solvents to obtain the octreotide acetate sustained-release microsphere.

The invention relates to the field of pharmaceutical preparations, in particular to a ramelteon liquid preparation as well as a preparation method and application thereof. The preparation comprises the following components: ramelteon, a first solvent, a second solvent and a third solvent, and optionally comprises one or more of water, a solubilizer, a surfactant, a polymer film-forming material, a plasticizer, a flavoring agent and a diluent. The preparation is high in stability, convenient to take and high in bioavailability, effectively overcomes the defects in the prior art, and has commercial application value.

The invention provides donepezil sustained-release microspheres and a preparation method, a pharmaceutical preparation and application thereof. The preparation method comprises the following steps: forming a water phase (containing a surfactant, an osmotic pressure regulator and water, and regulating the pH value with a pH regulator); forming an oil phase (comprising donepezil, a carrier material and an organic solvent); and adding the oil phase into the water phase, dispersing to form a pre-emulsion, performing membrane emulsification on the pre-emulsion to form an emulsion, and finally curing, washing and freeze-drying the emulsion to obtain the donepezil sustained-release microspheres. The preparation process is stable and controllable, the batch-to-batch repeatability is good, the surface of the microsphere is smooth and complete, the particle size distribution is uniform, the size is controllable, the microsphere has high drug loading capacity, long-term stable release can be realized, the injectability is excellent, the administration frequency can be reduced, and the adverse reaction of gastrointestinal tracts can be reduced.